Differentiation and Breakthrough: The Breakthrough Strategy of a Serial Entrepreneur in Medical Robotics

Recently, Arterial Network officially released the "2026 China Healthcare Industry Innovation Influence 50" list. Dr. Zhang Jian, founder and CEO of Puli Ark, was awarded the "Influential Entrepreneur" honor for his pioneering technological breakthroughs and excellent industrialization capabilities in the field of surgical robots.

This honor is not only a recognition of Dr. Zhang Jian's more than 20 years of dedication to the surgical robot field, but also an industry recognition of the differentiated innovation path of Puli Ark and its US parent company Noah Medical, which is "centered on clinical value".

NMPA Certification: Global All-Disposable Bronchoscope Robotic Platform

In November 2025, the PriBio bronchoscope robot was officially approved by the NMPA , becoming a global robotic platform that provides all-disposable bronchoscopes.

" Large-scale production immediately upon approval "—this phenomenon is extremely rare in the global surgical robot field. More noteworthy is that, unlike industry giants that rely on mature ecosystems, Puli Ark has no "big tree" to lean on, but it has carved out its own path by virtue of its generational advantage in "real-time image confirmation + all disposable consumables + small size".

High-precision navigation ≠ high-precision positioning: completing the crucial "arrival-confirmation" closed loop.

Why is the biopsy rate of first-generation bronchoscopic robots generally stuck at around 75%?

Dr. Zhang Jian provided the answer: "Navigation" is not the same as "confirmation".

The lungs can shift by 3 to 4 centimeters with each breath, while ground-glass nodules of about 1 cm are almost invisible under C-arm fluoroscopy. Navigation can only tell the doctor "we're nearby," but it cannot confirm "whether it has punctured a tumor."

The core patented 3D Imaging DT technology of Puli Baichuan integrates digital tomography, enhanced fluoroscopy, and surgical depth, which can correct the lesion position in real time during the operation and confirm whether the biopsy tool has actually entered the lesion.

In a match 2 study of 31 clinical cases:

• The biopsy tool achieved a 93.5% confirmation rate within the lesion[1]

• The consistency with the CBCT confirmation results was as high as 96.7%[1] 

From "accessible" to "visible," this is a key step that truly transforms clinical outcomes for Puli Ark.

Three-tiered value logic: Clinical value > Clinical efficiency > Clinical cost

Throughout Dr. Zhang Jian's product philosophy, a clear weighted logic has always been present:

Clinical value (weight 100) > Clinical efficiency (weight 10) > Clinical cost (weight 1)

"If a product can solve a clinical problem that others cannot solve, then it is a 100-point product."

This also explains why the Galaxy system, despite not being cheap overseas, still saw rapid sales growth— doctors are buying problem-solving capabilities, not just price.

Silicon Valley innovation combined with a Chinese landing: 2026 marks the "Year One of Commercialization in China" for Puli Ark.

Puli Ark adopts a unique two-way framework of "Silicon Valley innovation + China implementation":

•  United States: Technological innovation, patent strategy, clinical validation, and large-scale commercialization

China  : Large-scale manufacturing, quality assurance, cost optimization, and improved clinical accessibility

"Compared to American companies, we have lower costs, higher quality, and higher efficiency; compared to Chinese companies, we have US patents, which can lay a good foundation for future commercialization in the United States, Europe, and other overseas countries."

Conclusion: Let every arrival be seen.

Dr. Zhang Jian once said:

"I wanted to make robots when I was in high school."

From Harbin Institute of Technology to Columbia University, from Intuitive Surgery to Auris Health, from Yifei Automation and Akuyu to today's Puli Ark— he has spent more than 20 years turning a childhood idea into a robot that will revolutionize the diagnosis and treatment of early-stage lung cancer.

Artery Network's assessment of Puli Ark is:

Winning the world through differentiation.

We believe that this journey has only just begun.

Congratulations again to Dr. Zhang Jian on being named one of the "50 Most Influential People in Innovation in China's Healthcare Industry - Influential Entrepreneurs".

Puli Ark ensures that every arrival is seen.

References:

[1].

Disclaimer: The content on this platform is for academic exchange among medical professionals only and does not constitute any medical advice. Patients with medical needs should consult a doctor for professional guidance. The technical opinions of medical professionals published on this platform do not represent the position of this company.

Copyright of all content in this article belongs to Puli Ark. Unauthorized reproduction or adaptation in any form is prohibited. Our company assumes no responsibility for any losses caused by improper reproduction or citation of this article and reserves the right to pursue legal action against infringers.